Back

Cystic Fibrosis Course 13: CF Liver Disease Part 1

Liver health in cystic fibrosis (CF) is receiving increasing attention from clinical care providers, researchers, and individuals with CF and their families. There have been advancements in our understanding regarding what factors may contribute to liver dysfunction in CF, new tools to assess liver health, and questions about what therapies may help, or even worsen, liver health. As such, in 2024, updated consensus recommendations on the screening, monitoring, and treatment of hepatobiliary disease in CF were released.

The Hepatobiliary Disease in CF (Part 1 and 2) courses were designed to assemble these developments into an engaging and interactive teaching modality that core CF team members, as well as gastroenterologists and hepatologists less familiar with CF, could use to enhance their knowledge and understanding. To support CF healthcare teams in navigating these developments this topic is divided into two focused courses.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 2 creditsNursingUp to 2 creditsPharmacyUp to 2 credits

MOC types

ABP — Lifelong Learning and Self-AssessmentUp to 2 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 2 credits
  • MOC · Up to 2 points
  • Released
    Mar 1, 2026
  • Last day to claim credit
    Mar 1, 2028 1 year left